Allogene's first quarter of 2026 came down to two events that will shape the next several years of this allogeneic CAR T company. The first was clinical, and it cleared a gate. In April, the company reported the planned interim futility analysis of ALPHA3, its pivotal Phase 2 trial of cemacabtagene ansegedleucel (cema-cel) in first-line large B-cell lymphoma, and the study passed: 58.3% of patients in the cema-cel arm achieved minimal residual disease negativity against 16.7% in the observation arm, with no cytokine release syndrome, no immune-effector neurotoxicity, no graft-versus-host disease, and no treatment-related serious adverse events or hospitalizations. The second was financial, and it bought time. Allogene ended the quarter with $266.9 million of cash, cash equivalents and investments, then in April completed a public offering that raised $200.4 million in gross proceeds - roughly $188 million net - extending its runway into the first quarter of 2029.
The quarter's accounting was the quietest part of the story. GAAP net loss narrowed 29% to $42.6 million, or $0.18 per diluted share, from $59.7 million, or $0.28, a year earlier, as research and development expense fell 36% to $32.0 million following the previous year's workforce reduction and the reprioritization of resources onto the clinical programs. The company also took a modest step up in its 2026 guidance, raising forecast operating cash expense from roughly $150 million to $165 million on the timing of the ALPHA3 program. This is a company priced on cash and on binary clinical milestones, not on earnings - and the quarter delivered on the former while setting the latter in motion. The stock, which traded near $3.00 in mid-April just before the offering, drew down through the spring and summer before recovering, and sits around $2.07, with the cash raised in April representing roughly 64% of the current market value.